Siemens Healthineers (OTCMKTS:SMMNY) Upgraded at Sanford C. Bernstein

Siemens Healthineers (OTCMKTS:SMMNY) was upgraded by stock analysts at Sanford C. Bernstein to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

A number of other brokerages have also weighed in on SMMNY. Royal Bank Of Canada started coverage on shares of Siemens Healthineers in a report on Wednesday, December 17th. They issued a “moderate buy” rating on the stock. Zacks Research raised Siemens Healthineers from a “strong sell” rating to a “hold” rating in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft cut Siemens Healthineers from a “buy” rating to a “hold” rating in a research note on Thursday, December 4th. Four analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Siemens Healthineers Stock Up 0.6%

Shares of OTCMKTS:SMMNY opened at $27.33 on Tuesday. Siemens Healthineers has a fifty-two week low of $23.28 and a fifty-two week high of $30.19. The firm’s 50 day moving average price is $25.58 and its 200 day moving average price is $26.86.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.